This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Ninlaro (ixazomib)
General Description
Ninlaro (ixazomib) is a prescription medicine used to treat patients with multiple myeloma.
Getting Ninlaro (ixazomib) in India
Ninlaro (ixazomib)is approved in the U.S., Europe, and other countries, but it is not yet commercially available in India. However, eligible patients in India may access this important therapy through the Named Patient Program (NPP).
MitoGENE helps patients obtain Ninlaro (ixazomib) legally and safely, in collaboration with their treating doctor. We assist with documentation, import coordination, and delivery—ensuring full compliance with Indian regulatory guidelines.
If you or a loved one needs Ninlaro (ixazomib), MitoGENE is here to guide you through every step of the process.
Disease Indications:Multiple Myeloma
Manufacturer:Takeda Pharma A/S
Usage:Oral
Medicine Approved by:
- European Medical Agency (EMA)
- Food and Drug Administration (FDA)
- Health Canada
- Pharmaceuticals and Medical Devices Agency (PMDA)
- Therapeutic Goods Administration (TGA)
Available Dosage Form & Package:
- 3 capsules of 2.3 mg
- 3 capsules of 3 mg
- 3 capsules of 4 mg
Shipping:
Room Temperature Shipping. Ninlarois shipped under controlled room temperature conditions (15°C to 25°C) using standard logistics procedures.
Four Simple Steps to AccessNinlaro (ixazomib)
If Ninlaro (ixazomib) is not yet approved or available commercially in your country, MitoGENE can help you access it through a legal pathway. Here’s how:
